Eli Lilly and Company (NYSE:LLY) Stake Raised by Gulf International Bank UK Ltd

Gulf International Bank UK Ltd raised its stake in Eli Lilly and Company (NYSE:LLY) by 1.8% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 68,709 shares of the company’s stock after acquiring an additional 1,211 shares during the period. Eli Lilly and Company makes up 1.3% of Gulf International Bank UK Ltd’s portfolio, making the stock its 8th biggest position. Gulf International Bank UK Ltd’s holdings in Eli Lilly and Company were worth $53,452,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of the stock. Fuller & Thaler Asset Management Inc. boosted its position in shares of Eli Lilly and Company by 7.0% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 3,054 shares of the company’s stock valued at $1,640,000 after buying an additional 200 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in shares of Eli Lilly and Company by 1.2% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 26,029 shares of the company’s stock valued at $13,981,000 after buying an additional 315 shares during the last quarter. Optiver Holding B.V. purchased a new stake in shares of Eli Lilly and Company during the third quarter valued at $36,000. Personal CFO Solutions LLC boosted its position in shares of Eli Lilly and Company by 26.0% during the third quarter. Personal CFO Solutions LLC now owns 2,576 shares of the company’s stock valued at $1,384,000 after buying an additional 532 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Eli Lilly and Company by 81.4% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 25,002 shares of the company’s stock valued at $13,429,000 after buying an additional 11,217 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of several recent analyst reports. BMO Capital Markets increased their price objective on Eli Lilly and Company from $900.00 to $1,001.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Citigroup increased their target price on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. JPMorgan Chase & Co. increased their target price on Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. Finally, Jefferies Financial Group increased their target price on Eli Lilly and Company from $925.00 to $957.00 and gave the company a “buy” rating in a report on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $803.50.

Eli Lilly and Company Stock Performance

NYSE:LLY opened at $883.88 on Friday. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90. Eli Lilly and Company has a 12-month low of $434.34 and a 12-month high of $905.45. The stock has a 50-day moving average price of $798.59 and a 200 day moving average price of $728.91. The stock has a market capitalization of $840.05 billion, a P/E ratio of 130.17, a P/E/G ratio of 1.93 and a beta of 0.36.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Monday, May 6th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.53 by $0.05. Eli Lilly and Company had a return on equity of 56.98% and a net margin of 17.08%. The firm had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. During the same quarter last year, the business posted $1.62 earnings per share. The firm’s revenue was up 26.0% on a year-over-year basis. Equities research analysts forecast that Eli Lilly and Company will post 13.76 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 10th. Investors of record on Thursday, May 16th were given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 0.59%. The ex-dividend date was Wednesday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insider Buying and Selling

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 194,978 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $885.91, for a total transaction of $172,732,959.98. Following the completion of the transaction, the insider now owns 97,583,810 shares in the company, valued at approximately $86,450,473,117.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Donald A. Zakrowski sold 750 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares of the company’s stock, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 762,804 shares of company stock worth $648,109,138. 0.13% of the stock is owned by corporate insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.